•
Dec 31, 2019
LabCorp Q4 2019 Earnings Report
LabCorp's Q4 2019 results were announced, showing revenue growth and increased adjusted EPS.
Key Takeaways
LabCorp reported a 6% increase in revenue for Q4 2019, reaching $3.0 billion. Diluted EPS increased to $2.32, and adjusted EPS rose by 13% to $2.86. Free cash flow also increased by 21% to $442 million.
Revenue for Q4 2019 was $3.0 billion, a 6% increase year-over-year.
Diluted EPS for Q4 2019 increased to $2.32, up from $1.56 last year.
Adjusted EPS for Q4 2019 grew by 13% to $2.86.
Free cash flow for Q4 2019 was $442 million, a 21% increase year-over-year.
LabCorp
LabCorp
LabCorp Revenue by Segment
Forward Guidance
LabCorp anticipates revenue growth between 4.0% and 6.0% over 2019 revenue. Adjusted EPS is projected to be between $11.75 and $12.15, and free cash flow is expected to range from $950 million to $1.05 billion.
Positive Outlook
- Revenue growth of 4.0% to 6.0% over 2019 revenue of $11.55 billion, which includes the negative impact from the disposition of business of approximately 0.2% as well as the benefit from foreign currency translation of 0.4%.
- Revenue growth in LabCorp Diagnostics of 0.5% to 2.5% over 2019 revenue of $7.00 billion, which includes the negative impact from PAMA of approximately 1.3% as well as the benefit from one additional revenue day of 0.4% and foreign currency translation of 0.1%.
- Revenue growth in Covance Drug Development of 7.0% to 9.5% over 2019 revenue of $4.58 billion, which includes the negative impact from the disposition of business of approximately 0.5% as well as the benefit from foreign currency translation of 0.7%.
- Adjusted EPS of $11.75 to $12.15, an increase of 3.8% to 7.3% over 2019 adjusted EPS of $11.32.
- Free cash flow (operating cash flow less capital expenditures) of $950 million to $1.05 billion, compared to $1.04 billion in 2019.
Revenue & Expenses
Visualization of income flow from segment revenue to net income